{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:49:00Z","timestamp":1785415740328,"version":"3.56.0"},"reference-count":19,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2017,9,17]],"date-time":"2017-09-17T00:00:00Z","timestamp":1505606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Persistent minimal residual disease (MRD) after consolidation may indicate chemotherapy insensitivity in B\u2010precursor acute lymphoblastic leukemia (BP\u2010ALL). Given the strong association of MRD and outcome in non\u2010Down syndrome (non\u2010DS) BP\u2010ALL, it is likely that MRD levels are also of prognostic significance in DS BP\u2010ALL. We report here the successful use of blinatumomab, a bispecific T\u2010cell engager antibody construct, in a patient with DS BP\u2010ALL and persistent MRD at the end of consolidation. Blinatumomab has been shown to have excellent results in patients with relapsed\/refractory BP\u2010ALL. This patient had no significant toxicity and achieved MRD negativity after only one cycle of blinatumomab.<\/jats:p>","DOI":"10.1002\/pbc.26824","type":"journal-article","created":{"date-parts":[[2017,9,18]],"date-time":"2017-09-18T14:27:14Z","timestamp":1505744834000},"source":"Crossref","is-referenced-by-count":15,"title":["Blinatumomab activity in a patient with Down syndrome B\u2010precursor acute lymphoblastic leukemia"],"prefix":"10.1002","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3245-2218","authenticated-orcid":false,"given":"Aman","family":"Wadhwa","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology Department of Pediatrics University of Alabama at Birmingham  Birmingham Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Kutny","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology Department of Pediatrics University of Alabama at Birmingham  Birmingham Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana C.","family":"Xavier","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology Department of Pediatrics University of Alabama at Birmingham  Birmingham Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,9,17]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)05264-2"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-509463"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3446"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2016.1161185"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-132837"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400989"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.469"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.84"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08846.x"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21737"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.2209"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-560847"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-633685"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.7270"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-441030"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.3247"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.3301"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-580068"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.26824","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.26824","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T15:27:55Z","timestamp":1696001275000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.26824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,17]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1002\/pbc.26824"],"URL":"https:\/\/doi.org\/10.1002\/pbc.26824","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,17]]},"article-number":"e26824"}}